Optimized variants of anti-VEGF antibodies and methods of treatment thereof by reducing or inhibiting angiogenesis
US10072075B2 · kind B2 · utility
9Cited by
33References
48Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 23, 2016 |
| Grant date | Sep 11, 2018 |
| Priority date | — |
| Expiry date | Sep 23, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2310/16
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides anti-VEGF antibodies and compositions that include anti-VEGF antibodies (e.g., antibody conjugates, fusion proteins, and polymeric formulations), and uses thereof, for example for treatment of disorders associated with pathological angiogenesis. The present invention also provides methods of identifying antibody variants with improved properties, for example, enhanced binding affinity, stability, pharmacokinetics, and/or expression.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.